Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 35.39
TARO's Cash to Debt is ranked higher than
78% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.69 vs. TARO: 35.39 )
TARO' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 35.39

Equity to Asset 0.79
TARO's Equity to Asset is ranked higher than
84% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.61 vs. TARO: 0.79 )
TARO' s 10-Year Equity to Asset Range
Min: 0.23   Max: 0.81
Current: 0.79

0.23
0.81
F-Score: 6
Z-Score: 17.28
M-Score: -2.18
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Revenue Growth (%) 22.30
TARO's Revenue Growth (%) is ranked higher than
87% of the 626 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. TARO: 22.30 )
TARO' s 10-Year Revenue Growth (%) Range
Min: -6.8   Max: 34.7
Current: 22.3

-6.8
34.7
EBITDA Growth (%) 63.60
TARO's EBITDA Growth (%) is ranked higher than
97% of the 592 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. TARO: 63.60 )
TARO' s 10-Year EBITDA Growth (%) Range
Min: -24.3   Max: 63.6
Current: 63.6

-24.3
63.6
EPS Growth (%) 74.30
TARO's EPS Growth (%) is ranked higher than
97% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.40 vs. TARO: 74.30 )
TARO' s 10-Year EPS Growth (%) Range
Min: 0   Max: 102.1
Current: 74.3

0
102.1
» TARO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

TARO Guru Trades in Q2 2013

Jim Simons 163,200 sh (+30.14%)
» More
Q3 2013

TARO Guru Trades in Q3 2013

HOTCHKIS & WILEY 438,675 sh (New)
Steven Cohen 5,644 sh (New)
Jim Simons 213,100 sh (+30.58%)
» More
Q4 2013

TARO Guru Trades in Q4 2013

HOTCHKIS & WILEY 529,936 sh (+20.8%)
Jim Simons 235,473 sh (+10.5%)
Steven Cohen 4,701 sh (-16.71%)
» More
Q1 2014

TARO Guru Trades in Q1 2014

Jim Simons 268,400 sh (+13.98%)
Steven Cohen Sold Out
HOTCHKIS & WILEY 455,252 sh (-14.09%)
» More
» Details

Insider Trades

Latest Guru Trades with TARO



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 18.20
TARO's P/E(ttm) is ranked higher than
90% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 40.50 vs. TARO: 18.20 )
TARO' s 10-Year P/E(ttm) Range
Min: 3.14   Max: 477.06
Current: 18.2

3.14
477.06
P/B 6.30
TARO's P/B is ranked higher than
56% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. TARO: 6.30 )
TARO' s 10-Year P/B Range
Min: 1.07   Max: 6.3
Current: 6.3

1.07
6.3
P/S 8.40
TARO's P/S is ranked higher than
58% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. TARO: 8.40 )
TARO' s 10-Year P/S Range
Min: 0.61   Max: 8.6
Current: 8.4

0.61
8.6
PFCF 19.60
TARO's PFCF is ranked higher than
92% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. TARO: 19.60 )
TARO' s 10-Year PFCF Range
Min: 4.51   Max: 27.78
Current: 19.6

4.51
27.78
EV-to-EBIT 12.90
TARO's EV-to-EBIT is ranked higher than
90% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.97 vs. TARO: 12.90 )
TARO' s 10-Year EV-to-EBIT Range
Min: 4.6   Max: 59.6
Current: 12.9

4.6
59.6
PEG 0.30
TARO's PEG is ranked higher than
98% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 356.67 vs. TARO: 0.30 )
TARO' s 10-Year PEG Range
Min: 0.3   Max: 36.64
Current: 0.3

0.3
36.64
Shiller P/E 34.70
TARO's Shiller P/E is ranked higher than
85% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. TARO: 34.70 )
TARO' s 10-Year Shiller P/E Range
Min: 6.08   Max: 83.05
Current: 34.7

6.08
83.05
Current Ratio 4.15
TARO's Current Ratio is ranked higher than
84% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. TARO: 4.15 )
TARO' s 10-Year Current Ratio Range
Min: 0.79   Max: 7.27
Current: 4.15

0.79
7.27
Quick Ratio 3.69
TARO's Quick Ratio is ranked higher than
85% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.67 vs. TARO: 3.69 )
TARO' s 10-Year Quick Ratio Range
Min: 0.55   Max: 6.3
Current: 3.69

0.55
6.3

Valuation & Return

vs
industry
vs
history
Price/Net Cash 17.10
TARO's Price/Net Cash is ranked higher than
88% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. TARO: 17.10 )
TARO' s 10-Year Price/Net Cash Range
Min: 6.83   Max: 92.19
Current: 17.1

6.83
92.19
Price/Net Current Asset Value 9.60
TARO's Price/Net Current Asset Value is ranked higher than
88% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. TARO: 9.60 )
TARO' s 10-Year Price/Net Current Asset Value Range
Min: 4.1   Max: 82.69
Current: 9.6

4.1
82.69
Price/Tangible Book 6.30
TARO's Price/Tangible Book is ranked higher than
64% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.53 vs. TARO: 6.30 )
TARO' s 10-Year Price/Tangible Book Range
Min: 0.89   Max: 15.98
Current: 6.3

0.89
15.98
Price/DCF (Projected) 2.00
TARO's Price/DCF (Projected) is ranked higher than
88% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. TARO: 2.00 )
TARO' s 10-Year Price/DCF (Projected) Range
Min: 1.47   Max: 201.56
Current: 2

1.47
201.56
Price/Median PS Value 4.10
TARO's Price/Median PS Value is ranked higher than
52% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.23 vs. TARO: 4.10 )
TARO' s 10-Year Price/Median PS Value Range
Min: 0.18   Max: 4.33
Current: 4.1

0.18
4.33
Price/Graham Number 2.20
TARO's Price/Graham Number is ranked higher than
82% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. TARO: 2.20 )
TARO' s 10-Year Price/Graham Number Range
Min: 0.4   Max: 10.12
Current: 2.2

0.4
10.12
Earnings Yield (Greenblatt) 7.80
TARO's Earnings Yield (Greenblatt) is ranked higher than
84% of the 621 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.00 vs. TARO: 7.80 )
TARO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.7   Max: 21.8
Current: 7.8

1.7
21.8
Forward Rate of Return (Yacktman) 0.74
TARO's Forward Rate of Return (Yacktman) is ranked higher than
71% of the 622 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.99 vs. TARO: 0.74 )
TARO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -31.7   Max: 56.8
Current: 0.74

-31.7
56.8

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Taro Pharmaceutical Industries Ltd develops, manufactures & markets prescription & over-the-counter (OTC) pharmaceutical products & active pharmaceutical ingredients (APIs) for use in its finished dosage form products.
» More Articles for NYSE:TARO

Headlines

Articles On GuruFocus.com
Pharmaceutical Industry on the Cusp Of Change Jun 02 2014 
Teva Pharmaceutical (TEVA) Dividend Stock Analysis Jun 28 2013 
taro pharma could double Aug 26 2012 
What do people think of TARO Aug 26 2012 
TARO Shares are Mispriced Compared to Competitors Like Perrigo and Teva May 10 2012 
Sun Pharmaceutical Extends Tender Offer for Taro Dec 19 2008 

More From Other Websites
TARO PHARMACEUTICAL INDUSTRIES LTD Financials Jul 09 2014
Today Taro Pharmaceutical Industries (TARO) Hits New Lifetime High Jul 09 2014
Taro Annual Report For Fiscal Year Ended March 31, 2014 on Form 20-F Available Jul 08 2014
Taro Annual Report For Fiscal Year Ended March 31, 2014 on Form 20-F Available Jul 08 2014
Taro Pharmaceuticals: Last Week's Move Is Only The Beginning Jul 02 2014
Salix Pharma Hits A New High On Bullish Clinical-Trial Data Jul 01 2014
Novo, Other Medicals Display Healthy Action Jun 26 2014
Taro: The Best Opportunity In Pharma May 29 2014
Can Taro Pharmaceuticals Inject Some Growth Into Your Portfolio? May 28 2014
Taro Provides Results for Year Ended March 31, 2014 May 27 2014
Actavis Builds Base As Annual Earnings Keep Growing May 23 2014
Taro to Announce Results for Quarter and Year Ended March 31, 2014 May 19 2014
Investors bet Sun Pharma can restore Ranbaxy to health Apr 13 2014
Mylan Bid Gets Rejected, But Generic-Drugmaker Rises Apr 04 2014
Taro Announces Results of Its Extraordinary General Meeting of Shareholders Mar 27 2014
Taro Announces Results of Its Extraordinary General Meeting of Shareholders Mar 27 2014
BlueMountain Capital Management, LLC Urges Minority Shareholders of Taro Pharmaceutical Industries... Mar 20 2014
Glass Lewis Recommends Taro Pharmaceutical Shareholders Vote FOR BlueMountain Capital Management's... Mar 18 2014
ISS Recommends Taro Pharmaceutical Shareholders Vote FOR BlueMountain Capital Management's External... Mar 17 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide